Pfizer nets Alzheimer’s drug for $725 million
Pfizer’s crusade to find its next blockbuster has led to a $725 million deal with San Francisco company Medivation for its Russian allergy drug to fight Alzheimer’s disease.
Read MoreAuthor: Katrina Megget
Merck Serono gets in on Ablynx’s nanobodies
Merck Serono has joined forces with biopharmaceutical company Ablynx in a deal that could be worth more than 335 million euro to co-develop therapeutic proteins for two targets in oncology and immunology.
Read MoreMultaq cuts risk of stroke by a third
Sanofi-aventis’ potential blockbuster Multaq (dronedarone) has been shown to reduce the risk of stroke by more than a third in patients with an irregular heartbeat.
Read More- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
